Award Number: W81XWH-11-1-0553

TITLE: Mechanisms of Oral Tolerance Breakdown in Food Allergy

PRINCIPAL INVESTIGATOR: Dr. Talal Chatila

CONTRACTING ORGANIZATION: Boston Children’s Hospital
   Boston, MA 02115-5724

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
   Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
   Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and
should not be construed as an official Department of the Army position, policy or decision
unless so designated by other documentation.
**Aim 1** Th2 and mast-cell mediated suppression of allergen-specific iTReg cell response. The hypothesis is that the prevailing Th2 environment II4raF709 mice suppresses the generation of allergen-specific iTReg cells. Blockade of Th2 and mast cell pathways may not only inhibit anaphylaxis but also promote tolerance.

Aim 2 capacity of mast cell depletion to restore oral tolerance in established allergic sensitization. The hypothesis is the mast cell expansion perpetuates oral intolerance to allergen, and that their acute depletion enables tolerance induction in established food allergy. Aim 3 allergen-specific TR cell therapy in the treatment of established oral sensitization. The hypothesis is that allergen-specific iTReg cells of WT but not II4raF709 mice would rescue established oral allergic sensitization and suppress the Th-2 skewing and mast cell expansion.

**14. ABSTRACT**

**15. SUBJECT TERMS**- none provided

**16. SECURITY CLASSIFICATION OF:**

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

**17. LIMITATION OF ABSTRACT**

| UU |

**18. NUMBER OF PAGES**

| UU |

**19a. NAME OF RESPONSIBLE PERSON**

USAMRMC

**19b. TELEPHONE NUMBER** (include area code)
# Table of Contents

**Progress report for Award #**  
W81XWH-110553

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body</td>
<td>1-4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>4-5</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>4-5</td>
</tr>
<tr>
<td>References</td>
<td>5</td>
</tr>
<tr>
<td>Appendices</td>
<td>6-17</td>
</tr>
</tbody>
</table>
Contract No.: W81XWH-110553  
Principal Investigator: Dr. Talal Chatila  
Title: “Mechanisms of Oral Tolerance Breakdown in Food Allergy”


A. Specific Tasks

Task 1. Th2 and mast-cell mediated suppression of allergen-specific iT\textsubscript{R} cell response. The purpose of this task is to determine mechanisms by which allergic pathways prevent the acquisition of oral tolerance.

Task 2. Capacity of Mast Cell Depletion to restore oral tolerance in established allergic sensitization. The purpose of this task is to determine whether acute mast cell depletion enables the restoration of oral tolerance in mice with established allergic sensitization.

Task 3. Allergen-specific T\textsubscript{R} cell therapy in the treatment of established oral sensitization. The purpose of this task is to determine whether allergen-specific iT\textsubscript{R} cells of WT, but not \textit{Il4raF709}, mice would rescue established oral allergic sensitization.

B. Studies and Results

Our laboratory moved from UCLA to the Boston Children’s Hospital (BCH) in January 2012. In the process, we have successfully moved our animals and re-established our studies relevant to this grant proposal. We have also successfully published a high impact report demonstrating that regulatory T (T\textsubscript{R}) cell therapy rescues disease in food allergic \textit{Il4raF709} mice and resets a food allergy-associated gut microbiota signature into one characteristic of a tolerant state [1]. It should be noted that we have been hampered by the delay in the transfer of funds previously allocated to this project to the BCH. This issue appears to be finally on its way to resolution, and the transfer of these funds is scheduled to occur by the end of 2013. Below is a Task-by-Task breakdown of the progress we have made on this project.

Task 1  Th2 and mast-cell mediated suppression of allergen-specific iT\textsubscript{R} cell response.  
The purpose of this task is to determine mechanisms by which allergic pathways prevent the acquisition of oral tolerance.

\textbf{Task1: Results:} Under Task 1, we have proposed to test the hypothesis that the skewed Th2 environment present in the gut of food allergic mice suppresses the development of an effective induced regulatory T (iT\textsubscript{R}) cell response, and consequently subverts the induction of oral tolerance to allergens. To that end, wild-type (\textit{Il4RaY709}), single mutant (\textit{Il4RaF709}, \textit{Il4}–/–, \textit{Il13ra1}–/–, \textit{FcerIa}–/–) and double mutant (\textit{Il4raF709/Il4}–/–, \textit{Il4raF709/Il13ra1}–/–, \textit{Il4raF709/FcerIa}–/–) mice (n=10/treatment group/genotype) were to be tested for the induction of oral sensitization and anaphylaxis in response to with either OVA (100 \(\mu\)g) or OVA/SEB (100 \(\mu\)g/10\(\mu\)g) once weekly for 8 weeks by gastric gavage. The mice were also to be examined for their capacity to develop allergen specific iT\textsubscript{R} responses to OVA. As demonstrated in Figure 1, FceRI deficient \textit{Il4raF709} mice fail to develop.

As shown in Figure 1, deletion of \textit{FcerIa} in \textit{Il4raF709} mice inhibited anaphylaxis in response to OVA sensitization, consistent with the dependence of the food allergic response in these mice on IgE/mast cells (Figure 1A). Importantly, mast cell expansion and total (and OVA-specific) IgE responses were dependent on intact FceRI expression, as both were severely inhibited by FceRIa deficiency. Thus, the mast cells were demonstrated as requisite for the anaphylaxis and, more broadly, for an effective food allergen-directed Th2 response (as reflected by IgE production) in \textit{Il4raF709} mice. Similar results were found for IL-4-deficient \textit{Il4raF709} mice (data not shown). Studies on IL-13 deficient \textit{Il4raF709} mice are pending.
Figure 1. Dependence of the food allergic response in IlraF709 mice on IgE/FceRI. A. FceRla deficiency prevents anaphylaxis in response to OVA sensitization and challenge in IlraF709 (F709) mice. Single (FceRla−/− and Il4raF709) and double mutant (FceRI−/− Il4raF709) mice were sensitized with oral OVA/SEB (100 µg/10µg mix) once weekly for 8 weeks then challenged with OVA (5mg). N=4-9 mice per group. B, C. FceRla deficiency prevents mast cell expansion and attenuates IgE elevation in OVA/SEB sensitized F709 mutant mice.

Studies on iT_{R} cell production continue to proceed. Our preliminary results revealed that iT_{R} induction is increased in Il4raF709/FcerIa−/− double mutant mice. Studies on iT_{R} induction in the other proposed mice under task are pending.

Task1: mice used: We have budgeted 240 mice under this task. We have used 120 mice so far. The remaining mice will be used to finish the respective mandates under this task.

Task 2. Capacity of Mast Cell Depletion to restore oral tolerance in established allergic sensitization. The purpose of this task is to determine whether acute mast cell depletion enables the restoration of oral tolerance in mice with established allergic sensitization.

Task 2: Results: Under Task 2, we have proposed to either sham sensitize Il4raF709 and Il4raF709/Mcpt5-Cre/iDTR mutant mice or to subject them to oral sensitization with OVA (100 µg) or OVA/SEB (100 µg/10µg). Subgroups of mice were to be treated with PBS or diphtheria toxin (DT) delivered intraperitoneally (i.p.) concurrently with the oral sensitization once weekly on weeks 9-12. At the end of the sensitization protocol, the mice were to be challenged with OVA (5 mg) delivered by oral gavage, and analyzed for anaphylaxis, and allergen-related Th2 and Tr cell responses. In collaboration with Dr. Hans Oettgen at the BCH (co-author on references 1), we found that DT-mediated deletion of mast cells in Il4raF709/Mcpt5-Cre/iDTR mice resulted in the suppression of allergic sensitization and the promotion of allergen-specific Tr cell formation. These studies remain in progress.

Task 2: mice used: We have budgeted 120 mice under this task. We have used 60 mice. The remaining mice will be used to finish the respective mandates under this task.

Task 3. Allergen-specific Tr cell therapy in the treatment of established oral sensitization. The purpose of this task is to determine whether allergen-specific iT_{R} cells of WT, but not Il4raF709, mice would rescue established oral allergic sensitization.

Task 3: Results: Decisive progress have been made on Task3 of the proposal. We have now completed this task, showing that allergic sensitization and anaphylaxis in the Il4raY709F mutant mice, which are genetically prone to food allergy, can be both prevented by therapy with allergen-specific WT Tr cells (Figure 2) [1]. Furthermore, established disease can be cured by therapy with allergen specific WT TR cells (Figure 3). In contrast, therapy with allergen specific Il4raF709 TR cells failed to either prevent or cure food allergy, indicating that Th2 reprogramming of TR cells disrupts their function and prevents tolerance induction.

For disease prevention, groups of Il4raY709 (WT) and Il4raF709 (mutant) mice (n=5-10/group) were either sham sensitize with PBS or subjected to oral sensitization with OVA (100 µg) or OVA/SEB (100 µg/10µg) once a week for total of 8 weeks. iT_{R} cells were derived from CD4⁺CD62L low EQGP⁻ naïve T cells, isolated by cell sorting from WT (Il4raY709) and mutant (Il4raF709)D011.10⁻Foxp3EGFP⁺
splenocytes and lymph node cells. iTR cells, at 5x10^5/100 µl PBS/mouse, or PBS vehicle were administered intravenously (i.v.) at the start of allergen sensitization. The mice were further continued on the respective sensitization regimen (Sham versus OVA or OVA/SEB) once weekly for another 4 weeks, then challenged orally with OVA (5 mg by gavage). Results revealed that OVA or OVA/SEB sensitized Il4raF709 mutant mice suffered from anaphylaxis when orally challenged with OVA, as evidenced by drop in body core temperature, whereas similarly sensitized and challenged WT mice did not (Figure 2A). Importantly, treatment with WT DO11.10^+ TR cells rescued OVA-OVA/SEB sensitized Il4raF709 mice from anaphylaxis (Figure 1A). Total and OVA-specific serum IgE and serum MCP1 concentrations, determined by ELISA, and jejunal mast cell numbers, determined by tissue histology, were increased in OVA and OVA/SEB sensitized Il4raF709 mice, but not in sensitized WT mice (Figure 2B-E). Again, therapy with WT DO11.10^+ TR cells suppressed all 4 parameters in sensitized Il4raF709 mice (Figure 2B-E). In contrast to the above, therapy with Il4raF709 DO11.10^+ TR cells failed to prevent disease (data not shown), indicating that excessive Th2 signaling in TR cells, either genetically engineered or in the context of a profoundly skewed Th2 environment, is detrimental to their function.

Figure 2 (from Noval Rivas et al J Allergy Clin Immunol, 2013. 131(1): p. 201-12). Prevention of oral sensitization and anaphylaxis in Il4raF709 mice by TR cell therapy. Prevention of oral sensitization by antigen-specific TR cells. A. Il4raF709 and WT BALB/c control mice were either sham sensitized with PBS or sensitized with OVA (100µg) or OVA/SEB (100 µg/10 µg) by gastric gavage once weekly for 8 weeks. Select groups of mice were given intravenously at the start of the sensitization protocol (day 0) either 5x10^5 cells of DO11.10^+ TR cells, isolated from DO11.10^+Foxp3^{EGFP} mice, or PBS. At the end of the sensitization period, the mice were challenged with 5 mg OVA by gastric gavage and monitored for rectal temperature changes. B. Total (left) and OVA-specific serum IgE levels (right panel) measured following OVA challenge. C. Enumeration of mast cell infiltration of small intestinal tissues of sensitized mice. D. Serum mMCP-1 levels in mice after OVA challenge. E. Small intestinal histopathology of sham (PBS), OVA-sensitized and OVA sensitized, DO11.10^+ TR cell treated mice; arrows indicate mast cells (Toluidine Blue staining; 200X). Results represent data on 5-10 mice/group derived from two independent experiments. ***P<0.001 by two way ANOVA.

For disease cure, groups of Il4raY709 (WT) and Il4raF709 (mutant) mice (n=10/group) were either sham sensitized with PBS or subjected to oral sensitization with OVA (100 µg) or OVA/SEB (100 µg/10µg) once a week for total of 12 weeks. iTR cells were derived from CD4^{+}CD62L^{low}EGFP^{−} naïve T cells, isolated by cell sorting from WT (Il4raY709) and mutant (Il4raF709)DO11.10^{+}Foxp3^{EGFP} splenocytes and lymph node cells. iTR cells, at 5x10^5/100 µl PBS/mouse, or PBS vehicle were administered intravenously (i.v.) at the end of week 8 of allergen sensitization. The mice were further
continued on the respective sensitization regimen (Sham versus OVA or OVA/SEB) once weekly for another 4 weeks, then challenged orally with OVA (5 mg by gavage). Results revealed that OVA or OVA/SEB sensitized Il4raF709 mutant mice suffered from anaphylaxis when orally challenged with OVA, as evidenced by drop in body core temperature, whereas similarly sensitized and challenged WT mice did not (Figure 3A). Importantly, treatment with WT Il4raY709D011.10*Foxp3EGFP iT_R cells rescued OVA-OVA/SEB sensitized Il4raF709 mice from anaphylaxis (Figure 3A). In contrast, therapy with Il4raF709D011.10*Foxp3EGFP iT_R cells failed to rescue established disease (Figure 3A), indicating that excessive Th2 skewing of iT_R cells by the Il4raF709 mutation was detrimental to their function. Total and OVA-specific serum IgE, serum MCP1 concentrations and jejunal mast cell numbers were increased in OVA and OVA/SEB sensitized Il4raF709 mice, but not in sensitized WT mice (Figure 3B-C). Therapy with WT but not Il4raF709 DO11.10*Foxp3EGFP iT_R cells suppressed these findings in sensitized Il4raF709 mice (Figure 3B-C).

Figure 3. Cure of established food allergy in Il4raF709 mice by therapy with WT but not Il4raF709 iT_R cells. A. Core body temperature recording in groups of Il4raF709 mice that were either sham or OVA sensitized. The latter included groups of mice that were either sham treated or treated with WT or Il4raF709 DO11.10* iT_R cells. A. Core body temperature recordings following challenge. B. Total (left) and OVA-specific serum IgE levels (right panel). C. Serum MCP1 concentrations and jejunal mast cell numbers. *P<0.05, **P<0.01, ***P<0.001 by two way ANOVA.

**Task3: Mice Utilized:** We have originally budgeted a total of 180 mice. All the mice budgeted under this task have been utilized.

c) **Significance and achievements**

Our studies have established the capacity of therapy with allergen-specific iT_R cells to prevent and cure food allergy. These findings will enable future approaches that promote allergen-specific iT_R cell responses as means of curing food allergy. The role of the microbiota in the food allergic process, and its resetting in tolerance, are currently under active investigation in our laboratory. The studies on the microbiota in food allergy promise novel therapeutic approaches that aim to reprogram the microbiota in food allergy in favor of tolerance induction.

**Achievements**

1. Demonstrated efficacy of immunotherapy for the prevention of food allergy and for curing established food allergy.
2. Identified a profound defect in the capacity of Th2 reprogrammed iT_R cells (those carrying the Il4raF709 mutation) to mediate oral tolerance to food allergens.
3. Identified strategies to overcome food allergy in the context of a severely skewed Th2 environment that may reprogram the iT_R cells. These include mast cell depletion (Figure 1) or neutralization of the Th2 environment with anti-cytokine-cytokine receptor approaches (studies currently in progress).

**Difficulties:** Despite the delay in the transfer of funds, which has been a serious problem, no experimental difficulties have been encountered in studies carried out so far. Furthermore, we have
achieved significant progress in our studies, and anticipate completion of the proposed studies on time by the end of the funding period.

d) Plans
Studies on Aim 1 and 2 will be concluded within the forthcoming funding year and submitted for publication.

e) Project-related Publications.

F) Project-generated resources
The $\text{iIl4RaF709}$ mice were originally generated in our laboratory and have been deposited at the Jackson Laboratory (Bar Harbor, ME), where they are available to interested investigators.

G) Inventions and Patents: None.
A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis

Magali Noval Rivas, PhD,a,* Oliver T. Burton, PhD,b Petra Wise, PhD,a Yu-qian Zhang, PhD,a Suej A. Hobson, MD,a Maria Garcia Lloret, MD,a Christel Chehoud, BA,c Justin Kuczynski, PhD,f Todd DeSantis, MSc,c Janet Warrington, PhD,c Embriette R. Hyde, BSc,d,e Joseph F. Petrosino, PhD,d,f Georg K. Gerber, MD, PhD,g Lynn Bry, MD, PhD,g Hans C. Oettgen, MD, PhD,b Sarkis K. Mazmanian, PhD,b and Talal A. Chatila, MD, MSc* Los Angeles, San Bruno, and Pasadena, Calif, Boston, Mass, and Houston, Tex

Background: Commensal microbiota play a critical role in maintaining oral tolerance. The effect of food allergy on the gut microbiotal ecology remains unknown.

Objective: We sought to establish the composition of the gut microbiota in experimental food allergy and its role in disease pathogenesis.

Methods: Food allergy–prone mice with a gain-of-function mutation in the IL-4 receptor α chain (Il4raF709) and wild-type (WT) control animals were subjected to oral sensitization with chicken egg ovalbumin (OVA). Enforced tolerance was achieved by using allergen-specific regulatory T (Treg) cells. Community structure analysis of gut microbiota was performed by using a high-density 16S rDNA oligonucleotide microarrays (PhyloChip) and massively parallel pyrosequencing of 16S rDNA amplicons.

Results: OVA-sensitized Il4raF709 mice exhibited a specific microbiota signature characterized by coordinate changes in the abundance of taxa of several bacterial families, including the Lachnospiraceae, Lactobacillaceae, Rikenellaceae, and Porphyromonadaceae. This signature was not shared by similarly sensitized WT mice, which did not exhibit an OVA-induced allergic response. Treatment of OVA-sensitized Il4raF709 mice with OVA-specific Treg cells led to a distinct tolerance-associated signature coincident with the suppression of the allergic response. The microbiota of allergen-sensitized Il4raF709 mice differentially promoted OVA-specific IgE responses and anaphylaxis when reconstituted in WT germ-free mice.

Conclusion: Mice with food allergy exhibit a specific gut microbiota signature capable of transmitting disease susceptibility and subject to reprogramming by enforced tolerance. Disease-associated microbiota may thus play a pathogenic role in food allergy. (J Allergy Clin Immunol 2013;131:201-12.)

Key words: Food allergy, microbiome, microbiota, regulatory T cells, tolerance, anaphylaxis, IgE, 16S rDNA, IL-4 receptor

It is unquestionable that food allergy has become a major health problem in developing countries, where the prevalence reaches up to 6% among children and 3% among adults.1,2 Like other atopic diseases, food allergies have a strong genetic component.3 However, the incidence of food allergy has increased dramatically in the last decades, particularly in affluent societies, pointing to lifestyle-associated environmental factors acting on genetically susceptible hosts to promote disease.4 Evidence suggests that the microbial flora are a key environmental influence in programming oral tolerance.5 Their lack in germ-free (GF) mice is associated with the development of Th2 and IgE responses to dietary antigens.6,7 Microbial signals, such as those delivered by polysaccharide A of the commensal bacterium Bacteroides fragilis or by a mix of clostridial species, induce mucosal tolerance by promoting the formation of induced regulatory T (iTreg) cells from naïve CD4+ T-cell precursors.8,9 Polymorphisms in or deficiency of genetic elements encoding microbial sensors, such as CD14, a high-affinity receptor for bacterial LPSs, and Toll-like receptor 4, which mediates responses to LPSs, are associated with food allergy.10,11

Changes in the microbial flora have been implicated in the pathogenesis of several disorders associated with the more affluent lifestyle common in developed countries. Obesity in both human subjects and experimental mouse models is associated with alterations in the intestinal microbiota that appear to be pathogenic, given that the microbiota of obese subjects promote weight gain when transferred into GF mice.12-14 More limited data have been accrued in the study of allergic diseases. In suboptimally controlled asthmatic subjects, both bacterial burden and bacterial diversity were significantly higher compared with those seen in control subjects and correlated with bronchial hyperresponsiveness.15 The development of atopic and atop dermatitis is associated with altered early postnatal gut flora.16,17 In the

From the Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, David Geffen School of Medicine at the University of California at Los Angeles; the Division of Immunology, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston; Second Genome, Inc, San Bruno; the Alkek Center for Metagenomics and Microbiome Research, the Interdepartmental Program in Cell and Molecular Biology, and the Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston; the Center for Clinical and Translational Metagenomics, Department of Pathology, Brigham & Women’s Hospital, Harvard Medical School, Boston; and the Division of Biology, California Institute of Technology, Pasadena.

Current affiliation: Division of Immunology, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston, Mass.

Supported by National Institutes of Health grants AI 080002 (to T.A.C.), AI007512 (to O.T.B.), DK034854 and DK078938 (to L.B.), HL07627 (to G.K.G.), AI100839 (to H.C.O.), and DK078938 (to S.K.M.); a grant from the Alkek Foundation (to J.F.P.); and the Department of Defense Congressionally Directed Medical Research Program in Food allergy grant FA100085 (to T.A.C.).

Disclosure of potential conflict of interest: C. Chehoud, J. Kuczynski, T. DeSantis, and J. Warrington are employees of Second Genome. E. R. Hyde has received support from The Alkek Foundation. G. K. Gerber, L. Bry, and H. C. Oettgen have received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication January 31, 2012; revised October 18, 2012; accepted for publication October 22, 2012. Available online December 3, 2012.

Available online December 3, 2012.
case of food allergy and despite the well-known role of the commensal flora in oral tolerance induction, there is meager information on the status of the intestinal microbiota on disease onset and after tolerance establishment. One study found alterations in the microbiota of infants with milk allergy on diagnosis and again after treatment.18 Another study in which atopic dermatitis cohorts were examined for changes in the microbiota in association with allergic food sensitization found no such relationship.19 Limitations to the latter set of studies include reliance on bacterial culture methods, limited 16S RNA genotyping approaches, or both for microbiota analysis.18,19

In this study we employed a phylotyping approach using high-density 16S ribosomal RNA (rDNA) oligonucleotide microarrays (PhyloChip assay; Second Genome, San Bruno, Calif) and massively parallel pyrosequencing of 16S rDNA amplicons to investigate whether oral allergic sensitization to a dietary antigen is associated with a distinct intestinal microbiota signature. These studies were enabled by the use of a novel mouse model of food allergy that well replicates many of the features of the human disease. Using the same model, we also examined whether therapy with allergen-specific regulatory T (Treg) cells imparts a tolerance-associated signature on the host microbiota.

METHODS

Animals

BALB/cTac mice (wild-type [WT] and Il4raF709 mice) were originally from Taconic Farms (Germantown, NY) and maintained as a separate line in the investigator’s colony from which mice were used for the current studies. C.129.1Hd1raF709 (Il4raF709) mice were bred onto the investigator’s BALB/cTac line for 11 generations.20 Foxp3EGFP and DO11.10 Foxp3EGFP mice, both on a BALB/c background, were previously described.20-22 All mice were kept on an ovalbumin (OVA)–free diet (Harlan 2018SX, Indianapolis, Ind). They were housed together in the same colony in a specific pathogen-free environment and were 8 to 12 weeks old when used for studies. All experiments were carried out in accordance with the Institutional Animal Care and Use Committee policies and procedures of the University of California–Los Angeles and the Boston Children’s Hospital.

Sensitization and challenge protocols

Studies were conducted on female mice to eliminate confounding effects of sex on the results of the microbiota analyses. In separate experiments there were no significant differences between male and female Il4raF709 mice in terms of sensitization and response to allergen challenge. For sensitization, female WT and Il4raF709 mice were treated intragastrically with sterile PBS or 100 μg of OVA alone or together with 10 μg of staphylococcal enterotoxin B (SEB; Sigma-Aldrich, St Louis, Mo) in 100 μL of sterile PBS (saline) once weekly for 8 weeks. On the ninth week, mice were challenged intragastrically with 5 or 150 μg of OVA in 100 μL of PBS. Anaphylaxis was assessed in challenged mice by measuring changes in body temperature and recording symptom scores. Temperature changes were measured with a rectal temperature probe (RET3) coupled to the Physitemp Thermalet Model/TH-5 (Physitemp, Clifton, NJ). After OVA challenge, temperatures were measured every 5 minutes. Symptom scores were determined according to previously detailed criteria.22

For studies on flora-reconstituted GF mice, fecal pellets of either OVA-SEB–sensitized WT or Il4raF709 mice were collected on the eighth week of sensitization. The pellets were dissolved at 1 pellet (20-25 mg) in 100 μL of PBS and administered to GF mice at 200 μL per mouse. The mice were then sensitized with OVA/SEB for 8 weeks and challenged with OVA, as described above.

Tolerance induction

CD4+ DO11.10 Foxp3EGFP T cells, representing thymus-derived (natural) Treg cells that express the DO11.10 T-cell receptor (TCR), which recognizes the OVA232-339 peptide in the context of I-Ad, were isolated by means of cell sorting from DO11.10 Foxp3EGFP mice. On day 0 of the sensitization protocol, Il4raF709 mice were given 5 × 10^5 CD4+ DO11.10 Foxp3EGFP T cells by means of retro-orbital transfer. The mice were then sensitized intragastrically with 100 μg of OVA in 100 μL of PBS once weekly for 8 weeks. They were challenged on week 9 with 5 mg of OVA in 100 μL of PBS administered intragastrically and monitored for their core body temperature and symptom scores, as described above.

ELISA for murine mast cell protease 1 and total and OVA-specific IgE

A murine mast cell protease 1 (mMCP-1) ELISA was performed on serum samples by using a kit (eBioscience, San Jose, Calif). Total and OVA-specific IgE concentrations were measured by using sandwich ELISAs. For total IgE, the capture and biotinylated detection antibodies (rat anti-mouse IgE clones R35-72 and R35-118, respectively) and purified mouse IgE isotype standard antibody (clone C38-2) were from BD Biosciences (San Jose, Calif). For OVA-specific IgE, the plates were coated with 100 μg/mL OV A. The detection antibody was as above, whereas the standard was a purified anti-OVA monoclonal IgE antibody (AbD Serotec, Oxford, United Kingdom).

Histologic analysis and enumeration of mast cells

Intestinal mast cells were enumerated by means of microscopic examination of sections of paraffin-embedded jejunal tissues stained with toluidine blue. Mast cells were counted and averaged across 10 high-power fields spanning the entire jejunal section.

PhyloChip sample processing and hybridization

Fecal pellets were obtained from sham- and allergen-sensitized mice just before allergen challenge. DNA extraction was performed with the UltraClean Fecal extraction kit (Mo Bio, Carlsbad, Calif), according to the manufacturer’s instructions. A total of 50 to 100 ng of extracted DNA per sample was used to amplify bacterial 16S rDNA gene sequences by using PCR with the universal primers 27F (5’-AGAGTTTGATCCTGCGTCAAG-3’) and 1492R (5’-GGTACCTGTAGCTACCTT-3’). Amplified products were hybridized to G2 PhyloChip arrays (Second Genome), which display 1,016,064 16S rDNA oligonucleotide probes that track microbial population shifts across greater than 50,000 operational taxonomic units (OTUs), each mapped to the Greengenes taxonomy.23-25 OTUs are defined as organisms that share sequence similarity of greater than 99%. The hybridization procedures were as described in the aforementioned references.
Bioinformatics
Details of the PhyroChip data analyses, including data preprocessing and reduction, construction of sample-to-sample distance functions, ordination, clustering, and classification methods and phylogenetic tree construction and visualization, are detailed in the Methods section in this article’s Online Repository at www.jacionline.org.

Statistical analysis
Results of allergen challenge studies were analyzed by using 2-way ANOVA. The Adonis test was used for finding significant microbiota differences associated with discrete categorical or continuous variables. Taxa were in some cases filtered to those significantly increased in their ranked HybScore in one category compared with the alternate categories by using the Kruskal-Wallis (KW) test. A P value of less than .05 was considered significant. Subgroup analysis for phylogenetic diversity was carried out by using 1-way ANOVA.

Other methods
Flow cytometric analyses and intracellular cytokine staining, PhyroChip and 16S rDNA pyrosequencing methods, and related statistical analyses are detailed in the Methods section in this article’s Online Repository.

RESULTS
Oral allergic sensitization of Il4raF709 mice is associated with the acquisition of a specific microbiota signature
Il4raF709 mice carry a gain-of-function mutation in the IL-4 receptor (IL-4R) α chain that disrupts the binding of the Src homology domain 2–containing protein tyrosine phosphatase 1 (SHP-1) to the receptor subunit and leads to augmented signal transducer and activator of transcription 6 (STAT6) activation by IL-4 and IL-13.19 Il4raF709 mice, but not WT control mice, are particularly susceptible to oral sensitization with innocuous food allergens, such as the chicken egg protein OVA, and sensitized mice respond to oral challenge with anaphylaxis that proceeds in all allergens, such as the chicken egg protein OVA, and sensitized particularly susceptible to oral sensitization with innocuous food allergens, such as the chicken egg protein OVA, and sensitized mice were either sham sensitized with PBS or sensitized with OVA, either alone or mixed with the oral adjuvant SEB, by means of oral gavage once weekly for 8 weeks to determine whether oral allergic sensitization results in a change in the intestinal microbiota.19,20 As noted previously, OVA- and OVA/SEB-sensitized, but not sham-sensitized, Il4raF709 mice had anaphylaxis on oral challenge with OVA, as evidenced by the decrease in core body temperature, and onset of diarrhea and tissue edema (Fig 1, A, and data not shown).21 Anaphylaxis was associated with increased total and OVA-specific serum IgE antibody levels, mast cell expansion in small intestinal tissues, and increased serum concentrations of the mast cell protease mMCP-1 compared with unsensitized Il4raF709 mice (Fig 1, B-E). Comparison of OVA- and OVA/SEB-sensitized mice revealed concordant temperature and biomarker responses on OVA challenge but more robust responses with the sensitized mice revealed concordant temperature and biomarker responses on OVA challenge but more robust responses with the sensitized mice.21,22 Results revealed that the identified taxa successfully partitioned the mice into 2 distinct groups, with only 1 of 9 OVA plus OVA/SEB versus PBS groups. We used 2 ordination methods, nonmetric multidimensional scaling (NMDS) and hierarchical clustering-average-neighbor (HC-AN) analyses, which examine relationships between ecologic communities, such as those of the microbial flora, to determine whether those OTUs identified by using the KW filter discriminate between sham- and allergen-sensitized Il4raF709 mice.23 Results identified 10 OTUs, mainly Bacilli and Enterobacteriaceae species (Fig 3, A and B). Investigation of significant taxa the abundance of which best discriminates between sham- and allergen-sensitized Il4raF709 mice was carried out by using Prediction Analysis for Microarrays (PAM), an algorithm that uses a nearest shrunken centroid method to determine those OTUs most characteristic of a community.24 Results identified 10 OTUs, mainly Bacteriodetes, that discriminated between the 2 categories, including several expanded Porphyromonadaceae, Barnesiella, and Rikenellaceae species (Fig 3, C and D, and see Table E1 in this article’s Online Repository at www.jacionline.org). The alterations in the microbiota affected by oral allergen sensitization were further visualized by using a circular phylogenetic tree that displayed 45 differentially abundant OTUs, representing the 41 bacterial families covered by the 251 taxa that passed the KW filter. The abundance of the represented OTUs among the different samples was revealed by means of a heat map that ranges
from blue (decreased) to red (increased). There was a broad decrease in the abundance of a majority of the selected OTUs, especially those of the Lachnospiraceae families, in allergen-compared with sham-sensitized Il4raF709 mice, although there were notable exceptions, such as Lactobacillaceae, Porphyromonadaceae, and some Rikenellaceae and Lachnospiraceae species (Fig 4 and see Table E2 in this article’s Online Repository at www.jacionline.org). Overall, the results shown in Figs 3 and 4 confirmed the establishment of oral allergic sensitization in the Il4raF709 mice is associated with dysbiosis of the intestinal flora.

To confirm the results obtained with the PhyloChip analysis, we used direct, highly parallel pyrosequencing of 16S rDNA amplicons derived from fecal samples of separate independent cohorts of sham- and OVA-sensitized Il4raF709 mice. Results revealed that the microbial communities were significantly different between the 2 groups of mice (see Fig E1 in this article’s Online Repository at www.jacionline.org). With the caveat that the 16S rDNA pyrosequencing method had different depth of coverage and other technical differences compared with the PhyloChip analysis, several families and genera were also found by using the former method to differentiate between the 2 groups, including OTUs classifying to the genera Clostridium, Bacteroides, Alistipes, and Streptococcus (see Table E3 in this article’s Online Repository at www.jacionline.org).

Allergen-specific Treg cell therapy induces a tolerance-associated microbiota signature

We next examined whether the induction of a food allergy-associated microbiota signature can be suppressed by enforced tolerance with allergen-specific Treg cells. Accordingly, we compared the intestinal microbiota of Il4raF709 mice that have been sensitized with OVA or OVA/SEB with those of similarly sensitized mice that have been intravenously administered Treg cells bearing the DO11.10 TCR specific for the immunodominant OVA peptide 323-339 (OVA323-339). Therapy with Treg cells suppressed allergen sensitization and prevented the clinical, histologic, and serologic correlates of anaphylaxis (Fig 1). In contrast, therapy with CD4⁺DO11.10⁺Foxp3EGFP⁻ cells or with CD4⁺DO11.10⁺ cells that express a nonfunctional Foxp3 mutant protein did not induce tolerance (Noval Rivas et al, manuscript in preparation). Direct comparison of the microbiota of the 2 categories revealed that the intestinal microbiota of DO11.10⁺ Treg cell–treated and OVA-sensitized mice were significantly different in the abundance metrics from those of sham (PBS)–treated, OVA-sensitized Il4raF709 mice (Adonis P = .007). Analysis of those taxa passing the KW test for differences between the 2 categories identified 627 taxa to have different abundance levels. NMDS with these taxa shows relatively tight clustering of Treg cell–suppressed samples and a broader variation in the samples of the OVA- and OVA/SEB–sensitized but Treg cell–untreated samples. HC-AN with these KW-filtered OTUs showed complete segregation of the OVA- and OVA/SEB–sensitized samples from the Treg cell–suppressed samples (Fig 5, A and B). PAM analysis identified 10 OTUs that discriminate between the 2 groups: 8 members of the Firmicutes Lachnospiraceae family that are increased on tolerance induction and 2 in the Bacteroidetes Porphyromonadaceae family that are decreased on tolerance induction (Fig 5, C and D, and see Table E4 in this article’s Online Repository at www.jacionline.org).
A global representation of the effects of Treg cell therapy on the microbiota of allergen-sensitized mice was provided by a phylogenetic tree representation of 86 differentially abundant OTUs, representing the 78 bacterial families covered by the 627 taxa that passed the KW filter (Fig 6). There was a broad resetting by means of Treg cell therapy of the changes in the microbiota induced by allergen sensitization, with reversal of the shifts in the abundance of several Firmicutes Lachnospiraceae and Bacteroidetes Porphyromonadaceae and Rickenellaceae families induced on sensitization (see Table E5 in this article’s Online Repository at www.jacionline.org). However, although Treg cell therapy altered the microbiota of allergen-sensitized mice, it did not shift it back to baseline. Direct comparison of the microbiota of tolerized and sham-treated Il4raF709 mice revealed the 2 categories to be significantly different both in incidence and abundance (Adonis $P = .013$ and .011, respectively). KW filtering identified 786 taxa that had significantly different abundance levels in samples from sham-sensitized compared with tolerized mice and that completely segregated the 2 groups of samples into separate clusters (Fig E2, A and B, in this article’s Online Repository at www.jacionline.org). PAM analysis identified 10 OTUs that best segregated the 2 groups, most from the Firmicutes Erysipelotrichaceae family (see Fig E2, C and D, and Table E6 in this article’s Online Repository at www.jacionline.org). Overall, these results established that enforcement of oral tolerance by means of Treg cell therapy inhibited the emergence of...
the microbiota signature associated with experimental food allergy.

The microbiota changes of I4raF709 and WT mice are nonoverlapping

Oral sensitization of WT BALB/c mice with OVA/SEB does not induce appreciable IgE responses and systemic anaphylaxis on oral challenge with OVA. We set out to determine whether oral allergen sensitization of WT was associated with changes in the microbiota. Direct comparison of the microbiota of OVA/SEB-sensitized versus sham-sensitized WT mice did not reveal statistically significant differences between the 2 groups (data not shown). To determine whether the dysbiosis observed with allergen-sensitized I4raF709 mice was distinct from that of WT mice, we first compared the microbiota of sham-sensitized I4raF709 and WT mice. Direct comparison identified the microbiota of the respective category to be significantly different both in the incidence and abundance metrics (Adonis P = .031 and .032, respectively; see Fig E3 and Table E7 in this article’s Online Repository at www.jacionline.org). In a separate analysis direct, highly parallel pyrosequencing was performed on 16S rDNA amplicons from fecal samples of otherwise unmanipulated WT and I4raF709 littermate mice that were derived from matings of I4raF709 heterozygous parents and sharing the same cages. The results confirmed that the microbial communities of the respective group were significantly different (see Fig E4 in this article’s Online Repository at www.jacionline.org).

We then compared the intestinal microbiota of OVA/SEB-sensitized I4raF709 mice with those of similarly sensitized WT mice. NMDS and HC-AN analysis of 352 taxa identified by the KW filter to have differential abundance in OVA/SEB-sensitized I4raF709 versus WT mice completely segregated the samples into 2 distinct groups (Fig 7, A and B). Of the 10 taxa found by using PAM to best discriminate between the 2 groups, 9 were increased in I4raF709 mice (Ruminococcaceae, Rikenellaceae, and Porphyromonadaceae species; Fig 7, C and D, and see Table E8 in this article’s Online Repository at www.jacionline.org). These results were validated by using direct, highly parallel pyrosequencing of 16S rDNA amplicons derived from fecal samples of independent cohorts of OVA-sensitized WT and I4raF709 mice (see Fig E5 and Table E9 in this article’s Online Repository at www.jacionline.org).
We further examined the overlap of those taxa that were specifically increased, decreased, or unchanged on OVA/SEB sensitization of Il4raF709 versus WT mice (Fig 7, E and F). Finally, similar trends were obtained when the combined data from the OVA-sensitized and OVA/SEB-sensitized Il4raF709 mice were compared with those of OVA/SEB-sensitized WT mice (see Fig E6 in this article’s Online Repository at www.jacionline.org). Overall, these results established that successful oral allergic sensitization in the Il4raF709 mutant mice was associated with a specific microbial signature that was nonoverlapping with changes in the microbiota of similarly treated WT mice, which are otherwise nonresponsive to sensitization.

The microbiota of food allergic Il4raF709 mice transmit susceptibility to food allergy

To explore the functional implications of the changed microbial flora in experimental food allergy, we reconstituted WT GF mice with flora derived from either OVA-sensitized WT or Il4raF709 mice. Flora-replete WT mice were then sensitized with OVA/SEB for 8 weeks and challenged with OVA. 16S rDNA
Pyrosequencing analysis revealed the microbiota of the flora-replete mice segregated in accordance with the source of the input microbiota (fecal samples of OVA-sensitized WT vs IL4RAF709 mice; Fig 8, A). Results revealed that the WT GF mice that were reconstituted with flora of OVA-sensitized IL4RAF709 mice but not that of OVA-sensitized WT mice underwent anaphylaxis on challenge with a heightened oral dose of OVA (150 mg), as evidenced by a decrease in core body temperature and increase in serum mMCP-1 concentrations (Fig 8, B and C). Analysis of total and OVA-specific IgE responses revealed that although the total IgE levels were not significantly different between the 2 groups, the OVA-specific IgE response was significantly higher in those mice reconstituted with flora from OVA-sensitized IL4RAF709 mice (Fig 8, D). Further analysis revealed that the microbiota of the mutant mice, but not those of the WT control animals, elicited T[sub]H[2] skewing of the OVA-responsive CD4 T cells isolated from the mesenteric lymph nodes (Fig 8, E and F). These results indicate that the dysbiosis in the OVA-sensitized IL4RAF709 mice promoted allergen-specific IgE responses and systemic anaphylaxis, which is consistent with a pathogenic function of the microbiota of allergen-sensitized IL4RAF709 mice in fostering disease.

**DISCUSSION**

The studies reported herein identified several novel features of the microbiota in food allergy. First, the microbial communities of food allergy–prone IL4RAF709 mice were distinct at baseline from those of congenic but food allergy–resistant WT control mice, which is consistent with the sculpting of the gut microbiota by a genetically driven TH2 environment. Allergic sensitization of the IL4RAF709 mutant resulted in the further emergence of a food allergy–associated microbiota signature that was virtually nonoverlapping with the changes in the microbiota of similarly sensitized WT mice that otherwise did not have disease. Furthermore, tolerance enforcement by means of treatment with allergen-specific Treg cells prevented the development of the food allergy–associated microbiota signature in IL4RAF709 mice and resulted instead in the emergence of a distinct tolerance-associated signature. Finally, the functional relevance of food allergy–associated dysbiosis was revealed by the differential capacity of the flora of allergen-sensitized IL4RAF709 mice, but not those of sensitization-resistant WT mice, to upregulate OVA-specific T[sub]H[2] and IgE responses and to promote anaphylaxis when reconstituted in GF WT mice. Thus allergic dysbiosis
provides one mechanism contributing to the pathogenesis of food allergy.

The pathways involved in directing the changes in the microbiota of the food allergy–prone Il4raF709 mice remain unknown. However, it can be inferred that the altered microbial ecology in Il4raF709 mice, both at baseline and on sensitization, is related to the augmented signaling along the IL-4Rα–STAT6 axis induced by the F709 substitution. Enhanced STAT6 signaling can act through any one of several putative mechanisms to alter the microbiota, including alterations in epithelial-commensal flora interactions in the profile of defensins expressed in the gut (which in turn reflects on the microbiota profile), alterations in other
components of the innate and adaptive immune responses relevant to the microbial ecology, or both. Augmented Il4raF709–STAT6 signaling can also effect the gut microbiota by augmenting the expression of resistin-like b (Retnlb), which is expressed under basal conditions in gut goblet cells in a microbial flora-dependent manner and the expression of which is also induced by TH2 signaling. Our previous studies have documented the exaggerated upregulation of Retnlb in the lungs of Il4raF709 mice undergoing paradigms of allergic airway inflammation.

An interesting observation that emerges from these studies is the relationship of tolerance induction to the composition of the microbiota. Enforced tolerance resets the microbiota to a new signature distinct from those of both sham- and OVA-sensitized Il4raF709 mice. Significantly, it could be demonstrated that unlike WT mice, Il4raF709 mice exhibit defective formation and function of OVA-specific Foxp3+ iTreg cells on OVA sensitization (Noval Rivas et al, manuscript in preparation). Thus the loss of regulatory circuits restraining the TH2 response in the gut might underlie the shifts in the microbial flora both at baseline and on OVA sensitization of the food allergy–prone Il4raF709 mice.

The full mechanism or mechanisms by which the microbiota of allergen-sensitized Il4raF709 mice contribute to disease pathogenesis remain to be determined, but previous studies provide insights into how such changes might promote disease. Components of the microbiota have been demonstrated to directly affect
the differentiation, function, or both of Treg and effector T cells. Studies on mechanisms of tolerance induction by the commensal bacterium *Bacteroides fragilis* have demonstrated the capacity of its product polysaccharide A to promote Foxp3+ Treg cell formation by signaling through Toll-like receptor 2 receptors on T cells. Loss of polysaccharide A abrogated tolerance induction by *B fragilis* and promoted instead Th17 formation. These findings raise the possibility that the changes in the commensal flora in Il4raF709 mice might adversely affect iTreg cell formation and function. Yet another mechanism could involve the direct promotion of allergic inflammation by components of the food allergy–associated microbiota in a manner similar to the promotion of Th17 cells by segmented filamentous bacteria.
The association of oral allergic sensitization in a food allergy–prone experimental model with specific changes in the microbiota suggests that similar changes might be operative in the human disease. Some previous studies with bacterial cultures and early-generation 16S rDNA assays have intimated that such changes can indeed occur in the human host, although those observations have been confounded, possibly because of the technical limitations of these methodologies. Profiling of bacterial 16S ribosomal RNA by using rDNA arrays and deep sequencing approaches promises detailed characterization of the microbiota in different subsets of patients with food allergy. The results of such approaches might be useful in guiding the diagnosis and classification of different phenotypes of food allergy and in aiding therapeutic interventions, including those with probiotic bacteria, that aim to restore a tolerogenic microbiota.

Key messages
- The microbiota of food allergic hosts are altered in a specific, reproducible manner.
- They transmit disease susceptibility to naive, germ-free recipients.
- They are subject to reprogramming upon enforced tolerance with allergen-specific regulatory T cells.

REFERENCES